Immune Pharmaceuticals Inc

Immune Pharmaceuticals — Investor Presentation (February 2015)

26 slides from Immune Pharmaceuticals's investor presentation, Feb 10, 2015

  1. Slide 1: Corporate Presentation February 2015

    Slide 1: Corporate Presentation February 2015

    Corporate Presentation February 2015 NASDAQ: IMNP

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    Forward - Looking Statement This presentation and any oral statements made with respect to the information contained in this presentation contain forward - looking statements that involve risks and uncertainties regarding the operations and future results of Immune Pharmaceuticals, Inc . You are urg

  3. Slide 3: Immune

    Slide 3: Immune

    Up IMMUNE

  4. Slide 4: Immune Pharmaceuticals Overview

    Slide 4: Immune Pharmaceuticals Overview

    Immune Pharmaceuticals Overview Leadership Team in New York City • NASDAQ listed company (IMNP) with dual Biotech / Specialty Pharma Business Model • First in Class Phase 2 Biologic candidate, Bertilimumab , for Auto - Immune Diseases ▪ Targeted Personalized Antibody Therapeutic with Companion Diagn

  5. Slide 5: Clinical Stage Portfolio With Multiple Shots on Goal

    Slide 5: Clinical Stage Portfolio With Multiple Shots on Goal

    Clinical Stage Portfolio With Multiple Shots on Goal Resources Prioritized For Bertilimumab Phase II BP And UC Trials PROGRAMS Preclinical Phase 1 Phase 2 Phase 3 I NFLAMMATION Bertilimumab Bullous Pemphigoid IBD ( Crohn’s and Colitis) Severe Asthma NASH A NTIBODY NANOPARTICLE CONJUGATES NanomAbs ®

  6. Slide 6: Highly Experienced Leadership Team

    Slide 6: Highly Experienced Leadership Team

    Highly Experienced Leadership Team Management Daniel Teper , PharmD , MBA Founder & CEO and Director ; Novartis, GSK, Sanofi , Bionest Gad Berdugo , Msc , MBA EVP and Chief Financial Officer ; Abbott, Baxter, Lazard, Tegris Paul Nadler, MD, PhD EVP, R&D and Chief Medical Officer; National Cancer Ins

  7. Slide 7: 2015 Milestones/Stock Catalysts

    Slide 7: 2015 Milestones/Stock Catalysts

    2015 Milestones/ Stock Catalysts Major Milestones/ Stock Catalysts ▪ Partnering of AMIKET ▪ Orphan Drug designation for Bertilimumab in BP ▪ Initiation of UC phase II study with Berilimumab ▪ Results of Bullous Pemphigoid (BP) phase II study Other anticipated potential milestones/ stock catalysts ▪

  8. Slide 8: Potential New Model for Personalized Medicine

    Slide 8: Potential New Model for Personalized Medicine

    Potential New Model for Personalized Medicine 8

  9. Slide 9: Bertilimumab: Eotaxin-Targeted Therapy in Autoimmune Diseases

    Slide 9: Bertilimumab: Eotaxin-Targeted Therapy in Autoimmune Diseases

    Bertilimumab: Eotaxin - 1 Targeted Therapy in Autoimmune Diseases Identify diseases where Eotaxin - 1 plays a significant role such as: Bullous Pemphigoid , Ulcerative Colitis, Crohn’s , Severe Asthma, NASH Screen patients for high levels of Eotaxin - 1 in disease tissue Treat selected patients with

  10. Slide 10: Who are BP Patients? Why are they at risk?

    Slide 10: Who are BP Patients? Why are they at risk?

    Who are BP Patients? Why are they at risk?  Patients are often in terrible discomfort with blisters presenting all over the body, including the oral cavity and the eyes  If left untreated, the disease runs its course in 1 - 5 years, and ruptured blisters may become infected, leading to sepsis — a

  11. Slide 11: Bullous Pemphigoid, an Aggressive, Serious Disease

    Slide 11: Bullous Pemphigoid, an Aggressive, Serious Disease

    Bullous Pemphigoid , an Aggressive , Serious Disease, Can Lead to Life Threatening Conditions 11

  12. Slide 12: Why Steroids do not address the needs of BP patients

    Slide 12: Why Steroids do not address the needs of BP patients

    Why Steroids do not address the needs of BP patients Initial Control of the disease requires very high daily dose of oral steroids ( 1 mg/kg or around 60 mg prednisone) and high potency topical steroids Long - Term Control requires chronic use of high dose systemic steroids 75 % of Patients suffer f

  13. Slide 13: Eosinophils are Predominant in the BP Inflammatory Process

    Slide 13: Eosinophils are Predominant in the BP Inflammatory Process

    Eosinophils are Predominant in the BP Inflammatory Process Bertilimumab Neutralizes Eotaxin - 1 , a Key Regulator of Eosinophils Significant unmet need for targeted therapy with improved safety profile SOURCE: Dr. Neil Kormin , Case Western 13

  14. Slide 14: Bertilimumab Phase II Proof of Concept Trial in BP

    Slide 14: Bertilimumab Phase II Proof of Concept Trial in BP

    Bertilimumab Phase 2 Proof of Concept Trial in BP Goal: to reduce the use of steroids while achieving disease control and remission Trial Design ▪ Open - label single arm study ▪ 10 - 15 newly diagnosed moderate to severely extensive BP patients ▪ Drug administration of 10mg/kg (30 min. IV infusion)

  15. Slide 15: A differentiated approach to the treatment of moderate to severe Crohn's and Colitis

    Slide 15: A differentiated approach to the treatment of moderate to severe Crohn's and Colitis

    A differentiated approach to the treatment of moderate to severe Crohn’s and Colitis (IBD) IBD expected to grow to $ 12 B by 2024 driven by disease modifying biologic drugs (source: Global Data) Recent successful launch of Takeda’s Entyvio ( vedoluzimab ) and favorable phase Ii clinical data from Re

  16. Slide 16: Vanderbilt-NIH Clinical Study establishes Eotaxin as a Biomarker

    Slide 16: Vanderbilt-NIH Clinical Study establishes Eotaxin as a Biomarker

    Vanderbilt - NIH Clinical Study establishes Eotaxin - 1 as a Biomarker and Therapeutic Target in Ulcerative Colitis Tissue eotaxin - 1 significantly increased in more severe patients (based on Mayo Clinic Disease Activity Index, mucosal injury and Histology severity) Patients treated with anti - TNF

  17. Slide 17: Bertilimumab Proof-of-Concept Phase II Trial in Ulcerative Colitis

    Slide 17: Bertilimumab Proof-of-Concept Phase II Trial in Ulcerative Colitis

    Bertilimumab Proof - of - Concept Phase II Trial in Ulcerative Colitis Target Labeling ahead of Anti - TNFs in Moderate to Severe UC with Patient Selection based on Tissue Eotaxin 1 levels (Companion Diagnostic) Trial Design ▪ Double - blind placebo controlled trial in 42 patients with moderate to s

  18. Slide 18: Targeted Nanoparticles for Improved Cancer Therapy Outcomes

    Slide 18: Targeted Nanoparticles for Improved Cancer Therapy Outcomes

    © 2.0 TARGETED NANOPARTICL FOR IMPROVED CANCER THERAPY OUTCOMES Up IMMUNE

  19. Slide 19: NanomAbs: Pre-Clinical Proof of Concept

    Slide 19: NanomAbs: Pre-Clinical Proof of Concept

    In Vitro Pancreatic cancer Oenetration of Anti H Feritin NanomAb Pre - Clinical Proof of Concept with anti - HER 2 and anti - EGFR mAbs Novel proprietary mAb targets with strong internalization properties High Payload: Up to 20,000 molecules per nanoparticle Versatility of drugs to be delivered , no

  20. Slide 20: Phase III ready product for neuropathic pain

    Slide 20: Phase III ready product for neuropathic pain

    Phase Ill ready product athic Pain, positioned for out- i Up IMMUNE

  21. Slide 21: AmiKet: Significant Short Term Monetization Opportunity

    Slide 21: AmiKet: Significant Short Term Monetization Opportunity

    AmiKet : Significant Short Term Monetization Opportunity Advanced Partnering Discussions Ongoing • Significant late stage product opportunity in large and growing neuropathic pain market ($ 3.6 B - Datamonitor) with high unmet medical need; Focused physician audience (Pain Specialists and Neurologis

  22. Slide 22: AmiKet Non-Inferior to Gabapentin HD in Post Herpetic Neuralgia

    Slide 22: AmiKet Non-Inferior to Gabapentin HD in Post Herpetic Neuralgia

    AmiKet Non - Inferior to Gabapentin HD in Post Herpetic Neuralgia (PHN) Met primary endpoint: ▪ Efficacy superior to placebo, p = 0.044 ▪ Not inferior to gabapentin, p = 0.84 Results suggest non inferior efficacy to market leader and excellent side effect profile Primary Endpoint: Mean Pain Score Am

  23. Slide 23: Physicians express strong demand for a highly effective topical drug

    Slide 23: Physicians express strong demand for a highly effective topical drug

    Physicians express strong demand for a highly effective topical drug Source: Interviews The main advantage of AmiKet is that it is not a systemic drug, and would prescribe it as a monotherapy for many of my patients … ” - EU Pain Specialist, Ambroise Pare Hospital (France “… Since a topical treatmen

  24. Slide 24: AmiKet peak sales estimates

    Slide 24: AmiKet peak sales estimates

    AmiKet peak sales estimated at $ 250 M - 390 M for PHN** and DPN** with additional $ 345 M upside for CIPN** 200 400 300 0 100 98 294 317 79 AmiKet U.S . and EU peak net revenues by scenario ( 2024 ) Millions of dollars Inconsistent stakeholder experience 249 62 238 Strong commercial execution 392 1

  25. Slide 25: 2015 Milestones/Stock Catalysts

    Slide 25: 2015 Milestones/Stock Catalysts

    2015 Milestones/ Stock Catalysts Major Milestones/ Stock Catalysts ▪ Partnering of AMIKET ▪ Orphan Drug designation for Bertilimumab in BP ▪ Initiation of UC phase II study with Berilimumab ▪ Results of Bullous Pemphigoid (BP) phase II study Other anticipated potential milestones/ stock catalysts ▪

  26. Slide 26: Investment Highlights

    Slide 26: Investment Highlights

    Investment Highlights NASDAQ listed company (IMNP) with dual Specialty Pharma/ Biotech Business Model First in Class Phase 2 Biologic candidate, Bertilimumab , for Auto - Immune Diseases ▪ Targeted Personalized Antibody Therapeutic with Companion Diagnostic opportunity ▪ Focus on Bullous Pemphigoid

Source: SEC EDGAR · 8-K filed Feb 10, 2015

More decks from Immune Pharmaceuticals Inc